Luciferase Reporter Cell Line - Caov-3

Caov-3 is a human ovarian cancer cell line originally isolated from an ovarian adenocarcinoma. It is now widely utilized as an in vitro model for studying the biology of epithelial ovarian cancer. These cells typically exhibit adherent, epithelial-like growth characteristics and are highly valued in cancer research because they retain various properties closely associated with the pathogenesis and progression of human ovarian tumors—including malignant proliferative capacity, tumor-associated signal transduction activity, and responsiveness to a range of anticancer drugs. The Caov-3 luciferase reporter cell line is an engineered derivative of the parental Caov-3 line; it has been genetically modified to stably express a luciferase reporter gene. Through stable genomic integration and rigorous selection, the Caov-3-Luc reporter cell line maintains consistent levels of luciferase expression throughout successive passages. Researchers can quantitatively analyze cell number, viability, tumor burden, or cellular activity simply by adding an appropriate luciferase substrate and detecting the resulting bioluminescence signal.

The Caov-3 luciferase reporter cell line is broadly applicable to various fields of basic ovarian cancer research and drug development. In in vitro experiments, this cell line is ideally suited for assays involving cell proliferation, cytotoxicity assessment, high-throughput compound screening, evaluation of signal pathway inhibitor efficacy, and studies on combination therapy regimens. Researchers can treat Caov-3-Luc cells with candidate drugs, biologics, small-molecule inhibitors, natural products, or gene-regulating agents. Subsequently, by monitoring changes in luminescence intensity, they can conveniently and quantitatively assess the surviving tumor cell burden. This feature establishes the cell line as a powerful tool for evaluating drug dose-response relationships, comparing the potency of different therapeutic agents, and screening for compounds with anti-ovarian cancer activity. Furthermore, this reporter system provides robust technical support for fundamental research investigating tumor signal transduction pathways, apoptosis, cell cycle regulation, DNA damage response, epithelial tumor progression, and mechanisms of drug resistance.